1. Home
  2. MREO vs MPB Comparison

MREO vs MPB Comparison

Compare MREO & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • MPB
  • Stock Information
  • Founded
  • MREO 2015
  • MPB 1868
  • Country
  • MREO United Kingdom
  • MPB United States
  • Employees
  • MREO N/A
  • MPB N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • MPB Major Banks
  • Sector
  • MREO Health Care
  • MPB Finance
  • Exchange
  • MREO Nasdaq
  • MPB Nasdaq
  • Market Cap
  • MREO 369.2M
  • MPB 467.7M
  • IPO Year
  • MREO N/A
  • MPB N/A
  • Fundamental
  • Price
  • MREO $2.42
  • MPB $28.94
  • Analyst Decision
  • MREO Strong Buy
  • MPB Buy
  • Analyst Count
  • MREO 7
  • MPB 2
  • Target Price
  • MREO $7.71
  • MPB $36.00
  • AVG Volume (30 Days)
  • MREO 1.5M
  • MPB 138.5K
  • Earning Date
  • MREO 05-19-2025
  • MPB 04-23-2025
  • Dividend Yield
  • MREO N/A
  • MPB 2.74%
  • EPS Growth
  • MREO N/A
  • MPB 23.94
  • EPS
  • MREO N/A
  • MPB 2.88
  • Revenue
  • MREO N/A
  • MPB $181,865,000.00
  • Revenue This Year
  • MREO N/A
  • MPB $19.07
  • Revenue Next Year
  • MREO $56.11
  • MPB $11.53
  • P/E Ratio
  • MREO N/A
  • MPB $10.03
  • Revenue Growth
  • MREO N/A
  • MPB 8.94
  • 52 Week Low
  • MREO $1.58
  • MPB $19.75
  • 52 Week High
  • MREO $5.02
  • MPB $33.87
  • Technical
  • Relative Strength Index (RSI)
  • MREO 50.79
  • MPB 64.96
  • Support Level
  • MREO $2.28
  • MPB $26.16
  • Resistance Level
  • MREO $2.75
  • MPB $29.57
  • Average True Range (ATR)
  • MREO 0.16
  • MPB 1.10
  • MACD
  • MREO 0.00
  • MPB 0.19
  • Stochastic Oscillator
  • MREO 32.65
  • MPB 83.81

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

Share on Social Networks: